Kiadis and Organon enter agreement
Kiadis and Organon have entered into an evaluation agreement concerning the use of Kiadis' core on-line screening technology, the BioSelact, for the Reproductive Medicine discovery program at Organon.
Kiadis and Organon have entered into an evaluation agreement concerning the use of Kiadis' core on-line screening technology, the BioSelact, for the Reproductive Medicine discovery program at Organon.
The collaboration will see Organon supplying Kiadis with a proprietary target, and Kiadis providing Organon with novel active compounds against the target, utilizing its BioSelact technology. Organon is particularly interested in the ability of BioSelact technology to efficiently characterize bioactive compounds present in complex chemical mixtures. Financial details were not disclosed.
Ton Rijnders, vice president of research at Organon, said: 'Organon has selected BioSelact technology because it may accelerate the discovery programmes by rapid on-line confirmation of new novel active compounds. This is a great opportunity to evaluate its potential to identify new leads.'
Kiadis developed the BioSelact platform to allow for a revolutionary drug discovery approach that greatly enhances lead discovery and optimisation programmes. It allows the highly efficient screening of every compound source of synthetic or natural origin on virtually all pharmaceutical target classes. It has been successfully applied to pharmaceutical and nutraceutical discovery programmes.